These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 29334266)

  • 1. Hyaluronic acid modified daunorubicin plus honokiol cationic liposomes for the treatment of breast cancer along with the elimination vasculogenic mimicry channels.
    Ju RJ; Cheng L; Qiu X; Liu S; Song XL; Peng XM; Wang T; Li CQ; Li XT
    J Drug Target; 2018 Nov; 26(9):793-805. PubMed ID: 29334266
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antitumor efficacy of Lf modified daunorubicin plus honokiol liposomes in treatment of brain glioma.
    Liu S; Zhang SM; Ju RJ; Xiao Y; Wang X; Song XL; Gu LY; Cheng L; Li XT; Chen GR
    Eur J Pharm Sci; 2017 Aug; 106():185-197. PubMed ID: 28583810
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Liposomes, modified with PTD(HIV-1) peptide, containing epirubicin and celecoxib, to target vasculogenic mimicry channels in invasive breast cancer.
    Ju RJ; Li XT; Shi JF; Li XY; Sun MG; Zeng F; Zhou J; Liu L; Zhang CX; Zhao WY; Lu WL
    Biomaterials; 2014 Aug; 35(26):7610-21. PubMed ID: 24912818
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hyaluronic acid-modified liposomal honokiol nanocarrier: Enhance anti-metastasis and antitumor efficacy against breast cancer.
    Wang J; Liu D; Guan S; Zhu W; Fan L; Zhang Q; Cai D
    Carbohydr Polym; 2020 May; 235():115981. PubMed ID: 32122511
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination of targeted daunorubicin liposomes and targeted emodin liposomes for treatment of invasive breast cancer.
    Fu M; Tang W; Liu JJ; Gong XQ; Kong L; Yao XM; Jing M; Cai FY; Li XT; Ju RJ
    J Drug Target; 2020 Mar; 28(3):245-258. PubMed ID: 31462111
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Octreotide-modified liposomes containing daunorubicin and dihydroartemisinin for treatment of invasive breast cancer.
    Ju RJ; Cheng L; Peng XM; Wang T; Li CQ; Song XL; Liu S; Chao JP; Li XT
    Artif Cells Nanomed Biotechnol; 2018; 46(sup1):616-628. PubMed ID: 29381101
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Combination of Targeted Sunitinib Liposomes and Targeted Vinorelbine Liposomes for Treating Invasive Breast Cancer.
    Shi JF; Sun MG; Li XY; Zhao Y; Ju RJ; Mu LM; Yan Y; Li XT; Zeng F; Lu WL
    J Biomed Nanotechnol; 2015 Sep; 11(9):1568-82. PubMed ID: 26485927
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeted delivery of honokiol by zein/hyaluronic acid core-shell nanoparticles to suppress breast cancer growth and metastasis.
    Zhang Q; Wang J; Liu D; Zhu W; Guan S; Fan L; Cai D
    Carbohydr Polym; 2020 Jul; 240():116325. PubMed ID: 32475585
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of nanoscaled dual targeting drug-loaded liposomes on inhibiting vasculogenic mimicry channels of brain glioma.
    Xie HJ; Zhan-Dui N; Zhao J; Er-Bu AGA; Zhen P; ZhuoMa D; Sang T
    Artif Cells Nanomed Biotechnol; 2021 Dec; 49(1):596-605. PubMed ID: 34514904
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The efficacy of WGA modified daunorubicin anti-resistant liposomes in treatment of drug-resistant MCF-7 breast cancer.
    Liu S; Song XL; Wang YH; Wang XM; Xiao Y; Wang X; Cheng L; Li XT
    J Drug Target; 2017 Jul; 25(6):541-553. PubMed ID: 28277825
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Application of functional vincristine plus dasatinib liposomes to deletion of vasculogenic mimicry channels in triple-negative breast cancer.
    Zeng F; Ju RJ; Liu L; Xie HJ; Mu LM; Zhao Y; Yan Y; Hu YJ; Wu JS; Lu WL
    Oncotarget; 2015 Nov; 6(34):36625-42. PubMed ID: 26429872
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting Epirubicin Plus Quinacrine Liposomes Modified with DSPE-PEG2000-C(RGDfK) Conjugate for Eliminating Invasive Breast Cancer.
    Sun MG; Shi JF; Li XY; Zhao Y; Ju RJ; Mu LM; Yan Y; Li XT; Zeng F; Lu WL
    J Biomed Nanotechnol; 2015 Aug; 11(8):1339-53. PubMed ID: 26295137
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HA-DOPE-Modified Honokiol-Loaded Liposomes Targeted Therapy for Osteosarcoma.
    Zhang X; Chen H; Zhang Y; Huang Q; Feng J; Xing H; Fu X; Yan X; Zhang Y; Xu Q; Liang J
    Int J Nanomedicine; 2022; 17():5137-5151. PubMed ID: 36345507
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Functional paclitaxel plus honokiol micelles destroying tumour metastasis in treatment of non-small-cell lung cancer.
    Wang X; Cheng L; Xie HJ; Ju RJ; Xiao Y; Fu M; Liu JJ; Li XT
    Artif Cells Nanomed Biotechnol; 2018; 46(sup2):1154-1169. PubMed ID: 30043652
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhanced antitumor efficacy using epirubicin and schisandrin B co-delivery liposomes modified with PFV via inhibiting tumor metastasis.
    Jing M; Bi XJ; Yao XM; Cai F; Liu JJ; Fu M; Kong L; Liu XZ; Zhang L; He SY; Jia LQ; Li XT
    Drug Dev Ind Pharm; 2020 Apr; 46(4):621-634. PubMed ID: 32162988
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of tumor metastasis by targeted daunorubicin and dioscin codelivery liposomes modified with PFV for the treatment of non-small-cell lung cancer.
    Wang Y; Fu M; Liu J; Yang Y; Yu Y; Li J; Pan W; Fan L; Li G; Li X; Wang X
    Int J Nanomedicine; 2019; 14():4071-4090. PubMed ID: 31239668
    [No Abstract]   [Full Text] [Related]  

  • 17. Destruction of vasculogenic mimicry channels by targeting epirubicin plus celecoxib liposomes in treatment of brain glioma.
    Ju RJ; Zeng F; Liu L; Mu LM; Xie HJ; Zhao Y; Yan Y; Wu JS; Hu YJ; Lu WL
    Int J Nanomedicine; 2016; 11():1131-46. PubMed ID: 27042063
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of stealth liposomal daunorubicin plus tamoxifen on the breast cancer and cancer stem cells.
    Guo J; Zhou J; Ying X; Men Y; Li RJ; Zhang Y; Du J; Tian W; Yao HJ; Wang XX; Ju RJ; Lu WL
    J Pharm Pharm Sci; 2010; 13(2):136-51. PubMed ID: 20816001
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mitochondrial targeting liposomes incorporating daunorubicin and quinacrine for treatment of relapsed breast cancer arising from cancer stem cells.
    Zhang L; Yao HJ; Yu Y; Zhang Y; Li RJ; Ju RJ; Wang XX; Sun MG; Shi JF; Lu WL
    Biomaterials; 2012 Jan; 33(2):565-82. PubMed ID: 21983136
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibitory effects of compound DMBT on hypoxia-induced vasculogenic mimicry in human breast cancer.
    Li S; Zhang Q; Zhou L; Guan Y; Chen S; Zhang Y; Han X
    Biomed Pharmacother; 2017 Dec; 96():982-992. PubMed ID: 29208325
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.